ArticleAddictive behaviors2026
CBD, cannabis, or both? Examining use patterns and associated factors among U.S. youth and adults.
Article in Addictive behaviors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundCannabis and cannabidiol (CBD) use have grown recently among U.S. adults, yet little is known about their exclusive or combined use at the population level. This study sought to assess the prevalence and contributing factors of distinct use patterns.
methodsData from the 2023 National Survey of Drug Use and Health study were analyzed for adolescents (12-17,n = 11,572) and adults (18+,n = 45,133). Past-month cannabis and CBD use over the past 30 days, including patterns (non-use, exclusive, and dual-use), were reported and associated factors were examined by multinomial regressions.
resultsIn 2023, 15.4% and 9.8% of participants reported past-month cannabis and CBD use, respectively; while 8.9, 3.4%, and 6.4% reported exclusive cannabis use, exclusive CBD use, and dual-use, respectively. Cannabis and CBD use were most common among individuals aged 18-34, while dual use was highest in 18-25-year-olds (10.8%). Exclusive cannabis use peaked in 26-34-year-olds (14.8%), and exclusive CBD use was most prevalent in adults 65+ (5.0%). Youth females (vs. males) and those living above the poverty line (vs. in poverty) were more likely to report exclusive CBD use. Adolescents with fair or poor health (vs. excellent/good) were more likely to report exclusive cannabis (AOR = 3.2,p < 0.001), exclusive CBD (AOR = 3.0,p = 0.002), and dual-use (AOR = 3.0, p < 0.001). Based on adolescent regression results, state medical cannabis legalization was associated with higher exclusive cannabis use(AOR = 1.8,p = 0.01). Based on adult regression results, state medical cannabis legalization was associated with higher exclusive cannabis use (AOR = 1.5, p < 0.001) and dual-use (AOR = 1.5, p < 0.001).
conclusionsCannabis and CBD use exhibited distinct usage patterns. As cannabis legalization policies continue to evolve, public health professionals should focus on tailored interventions to mitigate potential side effects associated with complex cannabis use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.